Senior Pet Oral Topper — Palatability First, Documentation on the Jar

The problem this playbook solves: senior-pet toppers are undifferentiated powder with thin files — a documented EV topper with palatability-first design is the daily-ritual product the shelf lacks.

01 · The problem

Senior-pet shelves are walls of glucosamine powders and omega chews with interchangeable claims. The daily-bowl topper with a documented new-material story — characterized EVs, batch COA, veterinary-informed formulation — does not exist. Palatability decides everything: a topper the pet refuses is a refund.

02 · Scientific rationale

The oral format carries the same characterized EV base as the clinic line, in a palatability-first design — flavour base, fine-mill texture that binds to kibble, 30-day jar matched to the repurchase cycle — with palatability results on the spec sheet. Documentation differentiates: batch COA and the material chain printed accessibly for the pet-parent who reads.

03 · Program documentation

Palatability and texture specifications follow TONGNIAN's internal pet-format development files [6].

Method anchors: [1] EV biology and cargo [2] MISEV2018 characterization [3] category evidence (review or registered study) [4] formulation and handling guidance [5] national measurement guideline (2026 No. 17) [6] internal protocol and case documentation.

04 · Product architecture

05 · Process & QC

EV material runs on the fully enclosed 0.5–5 L micro-batch line with low-shear handling qualified at process validation [4]. QC panel design follows MISEV2018 [2] and the national measurement guideline (2026 No. 17, TONGNIAN a drafting organization) [5].

Fig. 1 — The topper program: jar, trial sachets, clinic card.

06 · Regulatory pathway: EU & US first

US: topper follows AAFCO labelling review with supplement-style positioning. EU: food-supplement framework with FEDIAF guidance, novel-food assessment where required. China blue-hat later on the same base. China blue-hat later — additional market on the same base formula. Companion-animal framing: wellness topper positioning, veterinary-informed formulation, no disease claims.

07 · Expected outcomes

• Palatability is the product: the flavour sachet program de-risks the trial.
• Documentation on the jar: every jar on the shelf makes the same claims; a printed batch COA and a readable material chain are the one thing a competitor cannot copy.
• 30-day jar = monthly rhythm matched to pet-parent purchase cycles.

Wording stays inside each destination market's rules; batch measurement does the persuading.

08 · Commercial framework

Sample kits in 3–5 days; pilot from 500 units; production from 2,000 units; standard lead 15 workdays — all indicative, quoted per request. White-label runs through the OBM program.

Request a quote · Line fact-sheet

References

1. Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977.
2. Théry C, et al. MISEV2018. J Extracell Vesicles. 2018;7(1):1535750.
3. Companion-animal regenerative market landscape — TONGNIAN desk research, 2026-08.
4. Guideline for Exosome Particle Size and Concentration Measurement (2026 No. 17) — TONGNIAN, drafting organization.
5. TONGNIAN network clinics. Anonymized internal protocol and case documentation (partner access under NDA).